Oncolytics: GOBLET Cohort 4 third-line anal cancer ORR 29%; median DOR ~17 months; files new patent application

ONCOLYTICS BIOTECH INC

GOBLET Cohort 4: 4/14 evaluable third-line anal cancer patients responded (ORR 29%), 2 CRs, 2 PRs; median DOR ~17 months vs historical ~10%.
Second-line anal cancer: pelareorep + atezolizumab achieved 30% ORR (vs 13.8% standard of care), median DOR 15.5 months (vs 9.5 months).
Company planning Type C meeting with FDA in Q1 2026 to discuss accelerated approval pathway for third-line anal cancer.
Filed Track 1 patent application for pelareorep manufacturing; expects final USPTO action in Q3 2026; claims could extend to 2044.
Additional patent applications planned for manufacturing and method-of-use to potentially extend coverage beyond 2044.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.